2seventy bio, Inc. (NASDAQ:TSVT) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET
Company Participants
Elizabeth Hickin - Head of IR
Nick Leschly - President and CEO
Chip Baird - COO
Steve Bernstein - Chief Medical Officer
Conference Call Participants
Yaron Werber - TD Cowen
Kelsey Goodwin - Guggenheim Securities
Daina Graybosch - Leerink Partners
Samantha Semenkow - Citi
John Newman - Canaccord Genuity
Operator
Good day, and thank you for standing by. Welcome to the 2seventy bio Third Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speaker's presentation there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker, Elizabeth Hickin, Head of Investor Relations. Please go ahead.
Elizabeth Hickin
Thank you, operator. This morning, 2seventy bio issued a press release on our third quarter 2023 financial results. The press release can be found in the Investors and Media section of the company's website at 2seventybio.com.
Speaking on the call today are Nick Leschly, Chief Kairos Officer; Chip Baird, Chief Operating Officer; and Steve Bernstein, Chief Medical Officer. Phil Gregory, Chief Scientific Officer, is also on the line for the Q&A session.
As a reminder, today's discussion will include forward-looking statements related to 2seventy bio's current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements include statements regarding our strategic plans, timelines and expectations and statements regarding our financial conditions, expectations and other future financial results, among others. Actual results may differ materially due to various risks uncertainties and other factors, including those described in the Risk Factors section of our most recent Form 10-K and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. You are cautioned not to place any undue reliance on these forward-looking statements. And except as required by law, we undertake no obligation to update or revise any forward-looking statements.
At this time, I would like to turn the call over to Nick Leschly. Nick?
Nick Leschly
Thank you, Liz. Good morning, everyone, and thank you for joining us as we discuss our third quarter results and business updates. While this quarter was challenging for 2seventy and the broader biotech markets, we continue to take actions to best position the business and our science for future success.